ClinConnect ClinConnect Logo
Search / Trial NCT00149149

Effect of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers

Launched by IMPERIAL COLLEGE LONDON · Sep 7, 2005

Trial Information

Current as of September 26, 2025

Completed

Keywords

Reduction In Nsaid Related Gut Damage

ClinConnect Summary

The study was about exploring the influence of zinc carnosine (ZnC) on changes in small bowel permeability caused by indomethacin.

Healthy volunteers (n = 10) participated in this double-blind randomised controlled crossover protocol. Each arm comprised two baseline urine collections, followed by a third at the end of that study period. In each arm, volunteers took ZnC (37.5 mg twice daily, orally) or placebo for 7 days, with indomethacin for the final 5 days.

Results were expressed as lactulose:rhamnose (L:R) ratios and mean values for each stage were therefore estimated: when taking pla...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Aged 18-35 years
  • Exclusion Criteria:
  • Conditions known to alter intestinal permeability, eg previous bowel surgery, celiac disease
  • Conditions where NSAIDs are contraindicated, eg asthma, renal failure, heart failure
  • Diabetes
  • Any other serious illness

About Imperial College London

Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.

Locations

London, United Kingdom

Patients applied

0 patients applied

Trial Officials

Raymond Playford, MD, PhD

Principal Investigator

Imperial College London

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials